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Introduction. Endometriosis is one of the most common benign disorders which aﬀects 10–15% of all women in reproductive age.
The association between endometriosis and ovarian cancer has been frequently described in the medical literature. Purpose. To
evaluate the literature for evidence of a correlation between endometriosis and ovarian cancer. Method. the English language
literature (online MEDLINE and EMBASE database) was searched using the keywords endometriosis combined with cancer,
tumour, tumor, carcinoma, or adenocarcinoma. All abstracts between January 1985 and August 2010 were reviewed. Full relevant
articles were critically assessed. Reference lists of included studies were checked. Results. Seven out of the eight studies, included in
our review, have shown an increased risk of ovarian cancer. However, the eﬀect size is modest (OR, RR, and SIR) ranging between
1.32 and 1.9 (95% CI). A causative relationship between the two incidences cannot be conﬁrmed. There is increasing evidence on
the role of genetic mutations in ovarian clear-cell and endometrioid carcinoma developing from endometriosis. Conclusion. More
evidence is needed before suggesting any change in the current management of endometriosis.
1.Introduction
Endometriosis is one of the most common gynaecological
disorders. It aﬀects 10–15% of all women in the reproduc-
tive years [1]. The incidence is 40–60% in women with
dysmenorrhoea and 20–30% in those with subfertility [1].
Although endometriosis is recognised as a benign disease,
its association with ovarian cancer has been frequently
described in the medical literature since 1925. In that
year, Sampson established the ﬁrst histopathological criteria,
which are still in use, to identify malignant tumours rising
from endometriosis: (1) clear evidence of endometriosis
close to the tumour, (2) the carcinoma must be seen to
arise in endometriosis, and not to be invading it from other
sources, and (3) presence of tissue resembling endometrial
stroma surrounding characteristic glands [2]. Later in 1953,
Scotthasaddedafourthcriterionwhichisthedemonstration
of a histology-proven transition from benign endometriosis
to cancer [3]. The application of all these four criteria has
rarely been fulﬁlled in the literature, which supports the idea
that the malignant transformation of endometriosis is a rare
event [4]. Yet, their stringent use may lead to underestimate
the real frequency of this phenomenon [4].
The aim of this paper is to systematically review the
literature evidence of a correlation between endometriosis
and ovarian cancer.
2. Methods
A protocol-driven systematic review was conducted in
accordance with the Centre for Reviews and Dissemination
(CRD) guidance. [5] The English language literature (online
MEDLINE and EMBASE database) was searched using the
keywords: endometriosis combined with cancer, tumour,
tumor,carcinoma,oradenocarcinoma.Allabstractsbetween
January1985andAugust2010werereviewedandfullarticles
of relevant publications in English language were retrieved.
A further systematic analysis of the publications included
in the reference lists was performed. All up-to-date reviews
on the same topic in the literature were assessed according
to Glasgow appraisal tool [6]. Case reports and case series
studies were excluded from our review.
3. Results
Seven reviews were found in the literature [4, 7–12], which
have addressed the association between endometriosis and2 ISRN Obstetrics and Gynecology
Table 1: A summery of the reviews’ ﬁndings.
Review
Language of
literature
searched
Type of studies included
Quality assessment
tool used in the
review
Overall results Application of results
Ness 2003
[7] English
In vitro, animal, clinical,
and epidemiologic
studies
Not speciﬁed
Consistent with the association
between endometriosis and
ovarian cancer.
Possible chemoprevention for
women with endometriosis.
Somigliana
et al. 2006
[4]
English Observational, cohort,
and case-control
Studies have been
critically analysed.
Increased risk of ovarian cancers:
eﬀect size: 1.3–1.9.
Modiﬁcations of the standard
treatment options for the
disease are not justiﬁable.
Vigano et
al. 2007
[8]
English
Observational, cohort,
and case-control
epidemiologic,
biological, and genetic
studies
Nineriteria, by
Austin Bradford
Hill [13]
The criterion of strength has not
been fulﬁlled. There were
insuﬃcient data for four criteria,
and four criteria were fulﬁlled.
The low magnitude of the risk
observed is consistent with the
view that ectopic
endometrium undergoes
malignant transformation
with a frequency similar to its
eutopic counterpart.
Nezhat et
al. 2008
[9]
English
Observational, cohort,
and case-control
epidemiologic,
histopathological, and
molecular studies
Not speciﬁed
Histological transition from
benign endometriosis to ovarian
malignancy.
The malignant potential of
endometriosis holds serious
implications for management.
Baldi et al.
2008 [10] English Not speciﬁed Not speciﬁed Further epidemiological and
genetic studies are required.
Appropriate physical
screening and imaging testing
are recommended.
Vlahos et
al. 2010
[11]
No search
criteria
speciﬁed
No search criteria
speciﬁed Not speciﬁed
Endometriosis is associated with
speciﬁc types of ovarian cancer
(endometrioid and clear cell).
More studies are needed to
establish the risk factors that
may lead to malignant
transformation.
Kobayashi
2010 [12] English
Studies on screening,
epidemiology, clinical
diagnosis, natural
history, preclinical and
clinical trials, and
promising molecular
targets on epithelial
ovarian cancer (EOC).
Not speciﬁed Ovarian endometrioma could be
viewed as a neoplastic process.
Understanding the
mechanisms of endometriosis
development and elucidating
its pathogenesis and
pathophysiology are intrinsic
to prevention.
ovarian cancer. A summarizing table of the reviews’ ﬁndings
was modiﬁed from the Glasgow appraisal tool (Table 1)[ 6].
Inourreview,11studieswereidentiﬁed,whichaddressed
the association between endometriosis and ovarian cancer
[14–24]. To remove the selection bias, studies on the sub-
fertility patients with endometriosis [14, 15] and studies on
endometriomas instead of endometriosis [16]w e r ee x c l u d e d .
Eight studies were included in the list [17–24]. Seven out of
the eight studies have shown an increased risk of ovarian
cancer. However, the eﬀect size is modest (odd ratio OR,
relative risk RR, and standardized incidence ratio SIR),
ranging between 1.32 and 1.9 (95% CI) Figure 1.
In epidemiological terms, when the RR is less than 2, a
careful assessment of the confounding factors must be con-
ducted before any conclusion of causality can be made [25,
26]. The previous epidemiologic deﬁnition was considered
when we selected the studies. Table 2 summarises the types,
sample size, followup time, confounding factors, and limita-
tion of each one of the eight studies included in our review.
4. Discussion
Despite the studies presented, the risk of ovarian cancer
among patients with endometriosis has always been con-
tentious. Endometriosis is usually conﬁrmed by laparoscopic
or histological examination, and many patients are unaware
of having the disorder. Therefore, identifying endometriosis
as a preceding factor of ovarian cancer is not possible in
manycases.Ontheotherhand,thenaturalhistoryofovarian
cancer is not well understood and the origin of the precursor
cell, especially for endometrioid and clear-cell variants, is
questionable. For these reasons, all studies in the literature
would struggle to establish a causal relationship between the
two entities. In this updated review we have tried to assess
the epidemiologic evidence in the literature and to discuss
ourﬁndingsinviewoftheothergenetic,immunological,and
biological relevant studies.
In our review we have found another group of eight
epidemiologic studies that correlated endometriosis withISRN Obstetrics and Gynecology 3
Table 2: Summary the types, sample size, followup time, confounding factors, and limitation of each one of the eight studies included in
our review.
Name of study Type
Mean of
followup
(years)
Size of
endometrio-
sis
cohort
Ovarian cancer
cases identiﬁed
in the cohort
Confounding factors
considered Main limitations
Aris 2010,
Canada [17]
Retrospective
cross-sectional 9 2521 41
Age, pregnancies, family
history, race, oral
contraceptive, tubal
ligation, hysterectomy and
breastfeeding
Retrospective collection of
data using a coded
computerised system.
Selection bias
Borgfeldt and
Andolf 2004,
Sweden. [18]
Case-control 10 28,163 81 Age and parity U s eo fc o h o r to fw o m e n
discharged from hospital with
a diagnosis of endometriosis.
This may lead to including
women with moderate and
severe endometriosis (hospital
stay patients) without
minimal and mild cases. This
may overestimate the risk
ratio. Selection bias.
Brinton et al.
1997, Sweden.
[19]
Retrospective
cohort study 11.4 20,686 29 Age and length of history of
endometriosis
Melin et al.
2006, Sweden.
[20]
Retrospective
cohort study 12.7 64,492 122 Age and type of surgery
performed.
Melin et al.
2007, Sweden.
[21]
Retrospective
cohort study 13.4 63 630 134 Age, parity, and type of
surgery performed
Modugno et al.
2004, USA.
[22]
Case-control 177
Age, parity, oral
contraceptive use, tubal
ligation, family history of
ovarian cancer, and study
site, gynaecological surgical
procedures
Recall and selection bias, as
the authors pooled data on the
history of endometriosis
reported by patients.
Ness et al.
2000. USA.
[23]
Case-control 66
Age, history of ovarian
cancer, parity,
breastfeeding, type and
length of each
contraceptive, tubal
ligation, hysterectomy,
ovarian operations.
Data was collected by case
interviews. Recall bias. Low
participation rates among
cases and controls.
Olsen et al.
2002, USA
[24]
Prospective
cohort study. 13 1,392 3
Age, education, marital
status, alcohol intake,
physical activity, smoking,
parity, oral contraceptive
use, HRT, history of
hysterectomy or dilatation
and curettage, BMI and
waist to hip ratio.
Reliance on self-reports of
endometriosis in this cohort
(a questionnaire). Recall bias.
The number of women who
developed ovarian cancer is
quite limited.
endometrioid and/or clear-cell ovarian carcinoma as a spe-
ciﬁchistologicalsubtype[27–34].Theyallreportedaspeciﬁc
link between endometriosis and endometrioid and/or clear-
cell ovarian carcinoma, with an OR ranging between 3.7 and
35.4 (CI 95%). We have excluded these case series studies
from our meta-analysis as there were not case-control or
cohort studies.
In a previous review, Somigliana et al. included two
other studies which assessed the risk of endometriosis on
ovarian cancer in infertile patients [4]. In the ﬁrst study,
infertile patients with endometriosis had the highest risk
with an SIR of 2.5 (95% CI, 1.3–4.2) compared to the general
population and an SIR of 4.2 (95% CI, 2.0–7.7) for the
group with primary infertility [15]. In the second study,
endometriosis and unknown cause of infertility resulted in
an independently associated elevation in ovarian cancer risk
after adjustment for standard confounding factors (odds
ratios (OR) 1.7 (95% CI, 1.1–2.7) and 1.2 (95% CI, 1.0–
1.4),resp.,)[14].Asinfertilityinvolvesmultipleconfounding
factors, and to remove the selection bias in our review, these
two studies were excluded from our review.
Additionally, we have excluded another study conducted
by Kobayashi et al.’s in Japan. They documented only endo-
metriomas and evaluated the risk of ovarian cancer based on
varying time periods from time of diagnosis of endometri-
oma [16]. Kobayashi et al. study did not account for patients4 ISRN Obstetrics and Gynecology
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Figure 1: A Forest pilot summarises the eight studies’ eﬀect size. Eﬀect size was measured in odd ratio (OR), standardized incidence
ratio (SIR), or relative risk (RR). The 95% conﬁdence interval is represented by the horizontal line, and the dimensions of the boxes are
proportional to the sample size.
with extraovarian endometriosis and only approximately
one-third of these patients had surgically conﬁrmed endo-
metriomas, with the remaining diagnoses made based on
ultrasonographic ﬁndings and physical exam only [16]. Dur-
ing followup of up to 17 years, 46 incidental ovarian cancers
were identiﬁed, translating into a standardized incidence
ratio of 8.95. This risk increased with age, with an incidence
ratio of 13.2 in women over age 50 [16].
Many genetic, biological, and immunological studies
have tried to address the causal relationship between endo-
metriosis and ovarian cancer. Diﬀerent types of genomic ins-
tability and mutations have been shown to occur in endome-
triosis and ovarian cancer [35, 36]. Moreover, microsatellite
analysis has demonstrated that loss of heterozygosity on p16
(Ink4), GALT (galactose-1-phosphate uridylyltransferase)
and p53, as well as on APOA2 (apolipoprotein A), a region
frequently lost in ovarian cancer, occurs in endometriosis
[37]. Another study by Baxter et al. has found the GSTM1
(glutathione S-transferase M1) null allele not to be an
endometriosis susceptibility allele [38]. However, it may pre-
dispose endometriotic lesions to malignant transformation
to endometrioid and clear-cell ovarian cancer [38]. Over-
expression of p53, oncogenic K-ras Pten deletion, and loss
of heterozygosity may also be involved in the endometriosis
transformation to ovarian cancer [39–41].
A vital factor in the development of both endometriosis
and malignancy is considered to be angiogenesis. In a study
by Hayrabedyan et al., the expression of several angiogenic
factors (interleukin-1 alpha (IL-1 alpha), Fibroblast growth
factor FGF-1, and S100A13) and a common pan-ovarian
carcinoma antigen were investigated, in several cases of
adenomyosis and ovarian endometriosis [42]. They have
shown that the common ovarian carcinoma marker, as well
as these angiogenic factors, was expressed in most of
the studied cases, implying possible common pathological
mechanisms shared between endometriosis and malignancy
[42]. In another study, Chou et al. illustrated that the
cyclooxygenase-2 (COX-2) overexpression rate was higher
in ovarian carcinoma associated with endometriosis than in
isolated ovarian carcinoma (27.8% versus 5.6%, P = 0.083)
[43]. They suggested that COX-2 over-expression may be
a result of the malignant transformation of endometriosis
to endometrioid type ovarian cancer or may represent an
interaction between the two cellular components [43]. By
contrast, Keita et al. suggested alteration in the expression
of interleukin-1 receptor antagonist IL-1RA, a key protector
against tumorigenic eﬀects of IL-1, as a possible link between
the endometrium, endometriosis, and endometrioid ovarian
cancer [44].
Recently, Wiegand et al. published new data implicating
ARID1A(AT-richinteractivedomain-containingprotein1A)
as a tumor-suppressor gene frequently disrupted in ovarian
clear-cell and endometrioid carcinomas [45]. They have fou-
nd ARID1A mutations in 55 of 119 ovarian clear-cell carci-
nomas(46%),10of33endometrioidcarcinomas(30%),and
none of the 76 high-grade serous ovarian carcinomas [45].
They demonstrated that the loss of the BAF250a protein was
correlated strongly with the ovarian clear-cell carcinoma
and endometrioid carcinoma subtypes and the presence of
ARID1A mutations [45]. By comparing ovarian clear-cell
carcinomas to their contiguous atypical endometriotic lesi-
onsintwopatients,theyhaveshownthatthesamemutationsISRN Obstetrics and Gynecology 5
may be present in the putative precursor lesions and in the
tumors. In contrast, the distant endometriotic lesions do not
have ARID1A mutations [45].
It seems, from the previous discussion, that there is insu-
ﬃcient evidence to suggest a speciﬁc gene mutation or a
speciﬁc biological pathway that predisposes endometriosis
patients to ovarian cancer. There is good evidence, how-
ever, to demonstrate the potential transformation from
endometriosis to ovarian endometriosis cell and clear-cell
carcinoma. The association between the two entities with
an eﬀect size of 1.32–1.9 may be due to sharing similar risk
factors, rather than a causal relation.
5. Conclusion
There is increased risk of ovarian cancers, speciﬁcally endo-
metrioid and clear-cell carcinoma, in women with endo-
metriosis. The estimated eﬀect size, however, is modest
varying between 1.32 and 1.9. A causative relationship bet-
ween the two incidences cannot be conﬁrmed. However,
there is increasing evidence on the role of genetic mutations
in ovarian clear-cell and endometrioid carcinoma devel-
oping from endometriosis. There are few gene mutations
involved,andyetmoreevidenceisneededbeforegeneralising
any mutation screening test or changing the treatment of
endometriosis to include radical excision in case of a positive
genetic mutation.
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